Donate today and join the fight to achieve global malaria elimination targets.
Together we can make a significant contribution to achieving malaria elimination targets.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
We have commenced a large project to express both spike and nucleoprotein of COVID-19, and other coronaviruses - SARS, MERS, OC43, 229E, NL63, and HKU1.
The antigens will be provided to Burnet’s Global Health Diagnostics Development Group for development of a COVID-19 point-of-care (PoC) diagnostic.
Our lab will contribute to PoC test development by providing novel technology to alter antigen structure and enhance sensitivity of PoC tests that can be monitored by Biolayer interferometry.
The Viral Entry and Vaccines Group have extensive expertise in the expression of viral glycoprotein antigens, manipulation of protein sequences to enhance expression and alter folding characteristics and optimisation of purification methods to increase yield and purity.
2020 -
Victorian Government (part of $1m for Diagnostics Development)
For any general enquiries relating to this project, please contact:
Program Director, Disease Elimination; Scientific Director, Burnet Diagnostics Initiative; Head, Global Health Diagnostics Development Laboratory; Co-Head, Drummer/Poumbourios Laboratory
To create and translate knowledge into better health, so no-one is left behind.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2022 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
